United States - English - NLM (National Library of Medicine)

lannett company, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 80 mg in 1 ml - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology ( 12.4 )] . genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology ( 12.4 )] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. lopinavir and riton

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lopinavir 100mg; ritonavir 25mg;   - film coated tablet - 100mg/25mg - active: lopinavir 100mg ritonavir 25mg   excipient: colloidal silicon dioxide copovidone opadry white 20c580015 sodium stearyl fumarate sorbitan laurate - lopinavir/ritonavir mylan is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lopinavir 200mg; ritonavir 50mg;   - film coated tablet - 200mg/50mg - active: lopinavir 200mg ritonavir 50mg   excipient: colloidal silicon dioxide copovidone opadry white 20c580015 sodium stearyl fumarate sorbitan laurate - lopinavir/ritonavir mylan is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older.

Kenya - English - Pharmacy and Poisons Board

cipla house, peninsula business park, ganpatrao… cipla house, peninsula business park, ganpatrao - lopinavir & ritonavir - tablet - lopinavir 200mg & ritonavir 50mg - lopinavir and ritonavir

Kenya - English - Pharmacy and Poisons Board

lopinavir/ritonavir - tablet - lopinavir usp 100mg, ritonavir usp 25mg - lopinavir and ritonavir

United States - English - NLM (National Library of Medicine)

laurus labs limited - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions (7.1) and clinical pharmacology (12.3)] .          

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [ see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see 

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Malta - English - Medicines Authority

accord healthcare limited - lopinavir; ritonavir - film-coated tablet - lopinavir 200 mg; ritonavir 50 mg - antivirals for systemic use